REFERENCES
1. Zernikow B, Michel E, Craig F, Anderson BJ: Pediatric palliative care: use of opioids for the management of pain. Paediatr Drugs 2009; 11: 129-51
2. Boland JW, McWilliams K, Ahmedzai SH, Pockley AG: Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: a systematic literature review. Br J Cancer 2014; 111: 866-73
3. Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 281-7
4. Brodeur G, Maris J: Neuroblastoma, 5th
edition. Philadelphia, J B Lippincott Company, 2006
5. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, Children’s Oncology G: Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363: 1324-34
6. Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG: Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett 2003; 197: 205-9
7. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA: Effect of a Chimeric Antiganglioside Gd2 Antibody on Cell-Mediated Lysis of Human Neuroblastoma-Cells. Cancer Research 1991; 51: 144-149
8. Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, Gan J, Hutson P, Seo S, Kim K, Goldberg J, Hank JA, Billups CA, Wu J, Furman WL, McGregor LM, Otto M, Gillies SD, Handgretinger R, Santana VM: Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol 2014; 32: 1445-52
9. Casey DL, Cheung NV: Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies. Cancer Immunol Res 2020; 8: 161-166
10. Anghelescu DL, Goldberg JL, Faughnan LG, Wu J, Mao S, Furman WL, Santana VM, Navid F: Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma. Pediatr Blood Cancer 2015; 62: 224-228
11. Sorkin LS, Otto M, Baldwin WM, Vail E, Gillies SD, Handgretinger R, Barfield RC, Yu HM, Yu AL: Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia. Pain 2010; 149: 135-142
12. Gorges M, West N, Deyell R, Winton P, Cheung W, Lauder G: Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children. Pediatr Blood Cancer 2015; 62: 29-34
13. Cata JP: Outcomes of regional anesthesia in cancer patients. Curr Opin Anaesthesiol 2018; 31: 593-600
14. Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA: Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology 2012; 116: 857-67
15. Vallejo R, de Leon-Casasola O, Benyamin R: Opioid therapy and immunosuppression: a review. Am J Ther 2004; 11: 354-65
16. Boland JW, Pockley AG: Influence of opioids on immune function in patients with cancer pain: from bench to bedside. Br J Pharmacol 2018; 175: 2726-2736
17. Rossaint J, Zarbock A: Perioperative Inflammation and Its Modulation by Anesthetics. Anesth Analg 2018; 126: 1058-1067
18. Yeager MP, Colacchio TA, Yu CT, Hildebrandt L, Howell AL, Weiss J, Guyre PM: Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 1995; 83: 500-8
19. Beilin B, Shavit Y, Hart J, Mordashov B, Cohn S, Notti I, Bessler H: Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg 1996; 82: 492-7
20. Furman WL, McCarville B, Shulkin BL, Davidoff A, Krasin M, Hsu CW, Pan H, Wu J, Brennan R, Bishop MW, Helmig S, Stewart E, Navid F, Triplett B, Santana V, Santiago T, Hank JA, Gillies SD, Yu A, Sondel PM, Leung WH, Pappo A, Federico SM: Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. J Clin Oncol 2022; 40: 335-344
21. Sokol EA, Engelmann R, Kang W, Pinto N, Starkey A, Lai H, Nadel H, Shulkin BL, Pu Y, Appelbaum D, Yanik GA, Cohn SL, Armato SG, Volchenboum S: Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer 2018; 65: e27417
22. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE: Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 1997; 121: 834-40
23. Provinciali M, Di Stefano G, Raffaeli W, Pari G, Desiderio F, Fabris N: Evaluation of NK and LAK cell activities in neoplastic patients during treatment with morphine. Int J Neurosci 1991; 59: 127-33
24. Mao M, Qian Y, Sun J: Morphine Suppresses T helper Lymphocyte Differentiation to Th1 Type Through PI3K/AKT Pathway. Inflammation 2016; 39: 813-21
25. Jacobs R, Karst M, Scheinichen D, Bevilacqua C, Schneider U, Heine J, Schedlowski M, Schmidt RE: Effects of fentanyl on cellular immune functions in man. Int J Immunopharmacol 1999; 21: 445-54
26. Provinciali M, DiStefano G, Stronati S, Raffaeli W, Pari G, Fabris N: Role of prolactin in the modulation of NK and LAK cell activity after short- or long-term morphine administration in neoplastic patients. International Journal of Immunopharmacology 1996; 18: 577-586
27. Caligiuri MA: Human natural killer cells. Blood 2008; 112: 461-9
28. Connolly C, Buggy DJ: Opioids and tumour metastasis: does the choice of the anesthetic-analgesic technique influence outcome after cancer surgery? Curr Opin Anaesthesiol 2016; 29: 468-74
29. Lee BM, Cata JP: Impact of anesthesia on cancer recurrence. Rev Esp Anestesiol Reanim 2015; 62: 570-5
30. Montagna G, Gupta HV, Hannum M, Tan KS, Lee J, Scarpa JR, Plitas G, Irie T, McCormick PJ, Fischer GW, Morrow M, Mincer JS: Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. Br J Anaesth 2021; 126: 367-376
31. Silagy AW, Hannum ML, Mano R, Attalla K, Scarpa JR, DiNatale RG, Marcon J, Coleman JA, Russo P, Tan KS, Fischer GW, McCormick PJ, Ari Hakimi A, Mincer JS: Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. Br J Anaesth 2020; 125: e402-e404
32. Thota RS, Ramkiran S, Garg R, Goswami J, Baxi V, Thomas M: Opioid free onco-anesthesia: Is it time to convict opioids? A systematic review of literature. J Anaesthesiol Clin Pharmacol 2019; 35: 441-452
33. Perry NJS, Buggy D, Ma D: Can Anesthesia Influence Cancer Outcomes After Surgery? JAMA Surg 2019; 154: 279-280
34. Meropol NJ, Porter M, Blumenson LE, Lindemann MJ, Perez RP, Vaickus L, Loewen GM, Creaven PJ, Wilkes KA, Giedlin MA, Caligiuri MA: Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin Cancer Res 1996; 2: 669-77
35. Xing W, Chen DT, Pan JH, Chen YH, Yan Y, Li Q, Xue RF, Yuan YF, Zeng WA: Lidocaine Induces Apoptosis and Suppresses Tumor Growth in Human Hepatocellular Carcinoma Cells In Vitro and in a Xenograft Model In Vivo. Anesthesiology 2017; 126: 868-881
36. Lynch C: Local Anesthetics as…Cancer Therapy? Anesth Analg 2018; 127: 601-602
37. Chang YC, Liu CL, Chen MJ, Hsu YW, Chen SN, Lin CH, Chen CM, Yang FM, Hu MC: Local anesthetics induce apoptosis in human breast tumor cells. Anesth Analg 2014; 118: 116-24
38. Li R, Xiao C, Liu H, Huang Y, Dilger JP, Lin J: Effects of local anesthetics on breast cancer cell viability and migration. BMC Cancer 2018; 18: 666
39. Page GG: Surgery-induced immunosuppression and postoperative pain management. AACN Clin Issues 2005; 16: 302-9; quiz 416-8
40. Page GG, Blakely WP, Ben-Eliyahu S: Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001; 90: 191-9
LEGENDS
Figure 1. Scatter plot of total weight-based morphine equivalent and tumor volume ratio
Figure 2. Scatter plot of total weight-based morphine equivalent and Curie Score